CDKN2A and neoplasm: For the 7 higher percentage PDAC tumours, 6 (86%) had loss of at least one copy of CDKN2A, TP53 and SMAD4, with homozygous loss of CDKN2A in 3 (43%) tumours and SMAD4 in one (14%) tumour.